# LYL273 for Patients With Relapsed or Refractory mCRC

Source: https://onco.cc/trials/nct05319314/  
OnCo record `nct05319314` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LYL273 in colorectal cancer, run by Lyell Immunopharma, Inc., now recruiting.

## Summary

LYL273 for Patients With Relapsed or Refractory mCRC is a phase 1/2 interventional study registered as NCT05319314 by Lyell Immunopharma, Inc., with 155 participants planned, started 2022-08-01 and due to reach its primary completion in 2028-06. Interventions recorded: LYL273.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05319314
- Phase: 1/2
- Setting: A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of LYL273 in Patients With Relapsed or Refractory Metastatic Colorectal Cancer
- Sponsor: Lyell Immunopharma, Inc.
- Enrolled: 155

## Sources

- ClinicalTrials.gov NCT05319314: https://clinicaltrials.gov/study/NCT05319314

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- companies: [Lyell Immunopharma](https://onco.cc/companies/lyell-immunopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05319314.json